Status: Recruiting
Transition to KPL-387 Monotherapy Dosing & Administration Study
The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.
Participants needed: 80
Trial details
Phase: Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Kiniksa Pharmaceuticals International, plcUpdated: Jun 22, 2026Locations: 33
Eligibility criteria
Has well-controlled recurrent pericarditis (i.e., including having CRP < 0.5 mg/... [+2]
Has a diagnosis of pericarditis that is secondary to specific prohibited etiolog... [+11]